Daiichi Sankyo

China - ShanghaiBiotechnology1 H-1B visas (FY2023)

Focus: Daiichi Sankyo is a publicly traded biotechnology company headquartered in Shanghai, specializing in small-molecule therapeutics across oncology, cardiovascular, metabolic, neurology, and immunology indications.

Oncology Cardiovascular Metabolic Diseases Neurology

Profile data last refreshed 13h ago · AI intelligence enriched 3w ago

Funding Stage

PUBLIC

Open Jobs

About Daiichi Sankyo

AI assessmentNot Hiring

No open roles listed right now. Follow Daiichi Sankyo to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

5/9 — Partial

Company HealthSolid

Pipeline

Early-stage

50 total

LOE Risk

1 imminent

SAVAYSA

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

ENHERTU

Oncology

$10M

Peak

Antibody-drug conjugate driving 55% of company revenue; peak-stage asset with sustained market position.

Help build intelligence for Daiichi Sankyo

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

ENHERTU, a peak-lifecycle antibody-drug conjugate (ADC) generating $10M in Part D spending, anchors a diversified oncology portfolio with recent FDA approvals driving momentum.
Pipeline spans 30 active programs across Phase 1–3 with 5 Phase 3 programs underway, including datopotamab deruxtecan in NSCLC and advanced breast cancer with near-term catalysts.
Small-molecule expertise in cardiovascular (SAVAYSA/edoxaban) and metabolic disease provides stability alongside emerging oncology franchise.

Watch Out For

55% revenue concentration on ENHERTU creates dependency risk; SAVAYSA loses exclusivity in March 2028, eroding $5M in revenue with limited near-term replacement drivers.
Zero active job openings reported despite public-company scale suggests hiring freeze or limited external recruitment, constraining entry points.

Generated by Claude from Daiichi Sankyo's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

LOE Approaching1.6yr

Small-molecule anticoagulant facing loss of exclusivity in 2028; second-largest revenue contributor at risk.

TURALIO

Oncology

$2M

Peak12.0yr

Peak-stage oncology small molecule with long exclusivity runway through 2038.

VANFLYTA

Leukemia/Hematologic Malignancies

$1M

Growth7.2yr

Kinase inhibitor in growth phase with Phase 3 leukemia program active; mid-term LOE protection through 2033.

DATROWAY

EGFR-mutated NSCLC, TNBC, platinum-resistant cancers

Launch

Recently launched Trop-2-directed ADC; topoisomerase I inhibitor payload; Phase 3 program in NSCLC and TNBC with near-term catalysts.

BANAN

Bacterial Infections

LOE Approaching

Legacy oral cephalosporin approaching loss of exclusivity; non-core to current strategic focus.

PRELAY

Type 2 Diabetes

LOE Approaching

Thiazolidinedione facing exclusivity loss; minimal current commercial relevance.

DATROWAY

Advanced Cancers

Growth

Duplicate entry of recently launched ADC platform; confirms clinical momentum across oncology indications.

FLOXIN OTIC

Ophthalmic Infections

LOE Approaching

Topical fluoroquinolone with limited strategic priority; legacy asset.

Pipeline & Clinical Trials

Bempedoic acid and/or its fixed dose combination with ezetimibe

Primary Hypercholesterolemia

N/A

Clinical Trials (1)

NCT05798390Treatment With Bempedoic Acid And/Or Its Fixed-dose Combination With Ezetimibe in Routine Clinical Practice in Patients With Primary Hypercholesterolemia Or Mixed Dyslipidemia

N/A

Evolution of the Therapeutic Care in Metastatic Breast Cancer From 2008

Metastatic Breast Cancer

N/A

Edoxaban

Atrial Fibrillation

N/A

Clinical Trials (1)

NCT04594915Evaluation of Treatment Safety in Patients With Atrial Fibrillation on Edoxaban Therapy in Real-Life in Turkey

N/A

Computer Electronic Alert

Atrial Fibrillation

N/A

Clinical Trials (1)

NCT02339493Electronic Alerts for Stroke Prevention in Patients With Atrial Fibrillation or Atrial Flutter

N/A

Edoxaban

Venous Thromboembolism

N/A

Clinical Trials (1)

NCT02952599Edoxaban Treatment in Routine Clinical Practice in Patients With Venous Thromboembolism in Korea and Taiwan (ETNA-VTE-KOR-TWN)

N/A

Edoxaban

Atrial Fibrillation

N/A

Clinical Trials (1)

NCT02944019Edoxaban Treatment in Routine Clinical Practice for Patients With Non Valvular Atrial Fibrillation

N/A

Observation

Cardioembolic Stroke

N/A

Clinical Trials (2)

NCT05486351Keeping Oral o Parental AnticoaguLation in the Acute Phase of Cardioembolic Ischemic Stroke

N/A

NCT01496885Observational Study to Evaluate the Simplified-STroke REhabilitation Assessment of Movement (S-STREAM) Scale in Subjects Who Have Experienced a Nonhemorrhagic Ischemic Stroke

No drug

Advanced/Metastatic HER2-negative Breast Cancer

N/A

Clinical Trials (2)

NCT06585501A Study of Treatment Patterns in HER2-positive Unresectable and Advanced Gastric/ Gastroesophageal Junction Cancer in China

N/A

NCT06975371Real-World Outcomes of Patients With Metastatic Breast Cancer After Treatment With First-Line ET+CDK4/6i

Edoxaban

Non-valvular Atrial Fibrillation

N/A

Clinical Trials (1)

NCT04747496Real-world Study on Edoxaban Treatment for Patients With Non-valvular Atrial Fibrillation in China

N/A

denosumab

Rheumatoid Arthritis

N/A

Clinical Trials (1)

NCT01973569AMG 162 (Denosumab) Phase 3 Study (DESIRABLE Study) in Participants With Rheumatoid Arthritis on Disease-modifying Antirheumatic Drugs (DMARDs) Treatment

N/A

None

Breast Cancer

N/A

Clinical Trials (1)

NCT04807595Estimation of the Prevalence of HER2 Low and Describe the SoC, Treatment Patterns, and Outcome in Real-world Practice Among Unresectable and/or Metastatic Breast Cancer Patients With HER2 Low Status

N/A

Edoxaban

Heart Failure

N/A

Clinical Trials (1)

NCT02448901Influence of Edoxaban on Coagulability and Thrombin Generation: An in Vitro Study Focusing on Thrombelastography

N/A

TAXUS Liberté Paclitaxel-Eluting Coronary Stent

Coronary Artery Disease

N/A

data collection

Metastatic Non-small Cell Lung Cancer (NSCLC)

N/A

A Study to Investigate the Prevalence of Human Epidermal Growth Factor Receptor 2 (HER2) Immunohisto

Cervical Cancers

N/A

Clinical Trials (1)

NCT06925113A Study to Investigate the Prevalence of Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ and Characterize the Clinicopathologic Features of Gynecologic Cancers in Taiwan

N/A

Trastuzumab deruxtecan

Unresectable Breast Cancer

N/A

Clinical Trials (1)

NCT05945732DESTINY Breast Respond HER2-(Ultra)Low Europe

N/A

IMPROVE Stroke Care- Developing and Optimizing Regional Systems of Stroke Care

Acute Stroke

N/A

ImplemeNtation oF demOnstration pRoject for Health systeMs: Atrial Fibrillation (INFORM-AF) Part 1

Atrial Fibrillation

N/A

Archival tissue specimen and immunohistochemistry staining

Non-small Cell Lung Cancer

N/A

Clinical Trials (1)

NCT05769764A Study of Prevalence of HER3 Expression in Non-Small Cell Lung Cancer

N/A

Aspirin

Impaired Glucose Tolerance

N/A

Clinical Trials (1)

NCT00122447Cardiovascular Disease (CVD) Risk and Prevention in Early Glucose Intolerance

N/A

Metastatic Breast Cancer in Austria

Breast Cancer

N/A

Colesevelam HCl

Diabetes Mellitus, Type 1

N/A

Bempedoic acid

Primary Hypercholesterolemiia

N/A

Clinical Trials (2)

NCT06686615A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia

N/A

NCT04579367Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemia

No Drug

Diabetic Peripheral Neuropathic Pain

N/A

Clinical Trials (1)

NCT06546202Real-World Pharmacological Treatment Pattern of Neuropathic Pain in China

N/A

Non Interventional

Pseudoxanthoma Elasticum

N/A

Clinical Trials (1)

NCT05025722Pseudoxanthoma Elasticum (PXE) Natural History Biomarkers in PXE Individuals and Their Biological Non-PXE Siblings

N/A

Trastuzumab deruxtecan

HER2-positive Breast Cancer

N/A

Clinical Trials (1)

NCT05458401EUropean Real-world Experience Of Previously Treated Advanced/Metastatic HER2-positive Breast Cancer Patients Accessing Trastuzumab Deruxtecan

N/A

Exercise bout

Healthy

N/A

Clinical Trials (1)

NCT02565823The Effects of Exercise of Secreted Factors From Muscle and Adipose Tissue

N/A

not applicable

Ischemic Stroke

N/A

CPT-11 based regimens

Metastatic Colorectal Cancer

N/A

Clinical Trials (1)

NCT01039506An Observational Study of CPT-11 Based Regimens and UGT1A1 Genotypes in Metastatic Colorectal Cancer (mCRC)

N/A

Evolution of the Therapeutic Care in Lung Cancer in France Since 2015 (ESME LC)

Lung Cancer

N/A

Oral Anticoagulant Peri-procedural Management in Patients Undergoing an Oral Surgery, Implantology o

Oral Anticoagulants

N/A

CS-3150

Primary Aldosteronism

N/A

Clinical Trials (2)

NCT02890173Study of CS-3150 in Patients With Essential Hypertension

Phase 3

NCT02885662Study of CS-3150 in Patients With Primary Aldosteronism

N/A

Preventicus heartbeat app in combination with wearables

Atrial Arrhythmia

N/A

Clinical Trials (1)

NCT04579159The Smartphone and Wearable Detected Atrial Arrhythmia in Older Adults Case Finding Study (Smart in OAC - AFNET 9)

N/A

Addressing Real-world Anticoagulant Management Issues in Stroke

Stroke

N/A

Exercise Intervention

Healthy

N/A

Clinical Trials (1)

NCT03037216Investigation of Exercise Training-Induced Myokines and Adipolkines in Humans

N/A

Minimal documentation

Advanced Solid Tumor

N/A

PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Rea

Breast Neoplasms

N/A

Clinical Trials (1)

NCT05573893PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan

N/A

Edoxaban

Atrial Fibrillation

N/A

Clinical Trials (1)

NCT02950168Edoxaban Management in Diagnostic and Therapeutic Procedures

N/A

Study of the Risk Factors and Outcomes After Gastrointestinal Bleeding

Gastrointestinal Hemorrhage

N/A

mgt of bleeding concerns/complications of oral anticoagulants

Blood Coagulation

N/A

Triaxial accelerometry

Thromboprophylaxis

N/A

Clinical Trials (1)

NCT06110949Thromboembolic Risk Assessment in Patients Admitted With Acute Medical Diseases to Conventional and At Home Hospitalization

N/A

Edoxaban

Atrial Fibrillation

N/A

Clinical Trials (1)

NCT05804747A Study to Evaluate Effectiveness and Safety of Edoxaban in Patients 80 Years of Age or Older With Nonvalvular Atrial Fibrillation

N/A

National Register of Actionable Mutations

Solid Tumours in Advanced Stages

N/A

Tumor Imaging

Carcinoma, Non-Small-Cell Lung

N/A

OCT

Coronary Disease

N/A

Clinical Trials (1)

NCT03176810Comparison Between Optimal Coherence Tomography Guidance and Angiography Guidance in Percutaneous Coronary Intervention

N/A

No drug

Non-small Cell Lung Cancer

N/A

Clinical Trials (1)

NCT06809764Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)

N/A

Tenosynovial Giant Cell Tumors (TGCT) Observational Platform Project

Giant Cell Tumors

N/A

Clinical Trials (1)

NCT02948088Tenosynovial Giant Cell Tumors (TGCT) Observational Platform Project

N/A

Colesevelam HCl

Type 2 Diabetes Mellitus

N/A

Clinical Trials (1)

NCT00476710Effects of Colesevelam HCl On Bile Acid Kinetics

N/A

Villalta phone score > or = to 5

Post Thrombotic Syndrome

N/A

ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors

Bladder Cancer

N/A

Clinical Trials (1)

NCT06973161ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors

N/A

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 10 approved products, 137 clinical trials

Top TAs: Oncology, Cardiovascular, Metabolic Diseases

H-1B (2023): 1 approval

Publications: 50 in PubMed

Portfolio Health

Launch1 (10%)

Growth1 (10%)

Peak3 (30%)

LOE Approaching5 (50%)

10 total products

Therapeutic Area Focus

Oncology

4 marketed246 pipeline

Cardiovascular

1 marketed113 pipeline

Metabolic Diseases

1 marketed47 pipeline

Neurology

1 marketed25 pipeline

Immunology

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Research Publications(10)

Recent peer-reviewed publications with author affiliations at this company

A Bayesian Optimal Interval Design Considering Efficacy and Toxicity in Early Phase Basket Trials.

Pharmaceutical statistics

2026

PMID:42411136

Treatment patterns and outcomes of second/third-line therapy in advanced non-small cell lung cancer with actionable genomic alterations (RECAP).

ADCINJECTION · INJECTABLE

deruxtecan-dlnk, is a Trop-2-directed antibody-drug conjugate. The antibody is a humanized anti-Trop2 IgG1. The small molecule, DXd, is a topoisomerase I inhibitor attached to the antibody by a cleavable linker. Following binding to Trop-2 on cells, including tumor cells, datopotamab deruxtecan-dlnk undergoes internalization and intracellular linker cleavage by lysosomal enzymes. Upon release, the membrane-permeable DXd causes DNA damage and apoptotic cell death. Datopotamab deruxtecan-dlnk had anti-tumor activity in mouse models of lung cancer including EGFR-mutated and breast cancer.

Respiratory

2 marketed8 pipeline

Nephrology

9 pipeline

Gastroenterology

6 pipeline

Clinical & experimental metastasis

Showing 5 of 10 publications

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Daiichi Sankyo

About Daiichi Sankyo

Why Work Here

Key Products

Watch Out For

Products & Portfolio (6)

Key Products by Revenue

Other Products (2)

Pipeline & Clinical Trials

Recent News · Daiichi Sankyo(10)

Open Jobs (0)

Hiring Trend

Visa Sponsorship

Research Publications(10)